Back to Market返回行情

DTIL Precision BioSciences, Inc.

USHealthcare
$8.92-3.88%OpenMarket Cap: $114.4M

As of 2026-07-09 12:37

Why DTIL matters now

Precision BioSciences, Inc. (DTIL) is a US stock in Healthcare. The latest InvestLog snapshot shows $8.92 with -3.88% on the session and $114.4M in market capitalization; recent performance reads 1-month -1.30% and YTD +63.70%.

The latest financial table shown here is Q1 2026, with revenue of $10.8M, net income of $-18.4M, and EPS of $-1.44. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -67.3%.

The latest indexable market news headline is "Strength Seen in Precision BioSciences (DTIL): Can Its 12.3% Jump Turn into More Strength?" from Zacks Investment Research.

Additional event context on this page matters because analyst consensus is Buy with a median target of $19.50; recent insider activity includes Buehler Kevin filing A-Award. These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

PEG

P/B

1.15

P/S

1.94

EV/EBITDA

-0.41

DCF Value

$-12.53

FCF Yield

-67.3%

Div Yield

0.0%

Margins & Returns

Gross Margin

97.0%

Operating Margin

-86.8%

Net Margin

-98.7%

ROE

-81.2%

ROA

-30.9%

ROIC

-28.4%

Financials

PeriodRevenueNet IncomeEPS
Q1 2026$10.8M$-18.4M$-1.44
Q4 2025$34.2M$19.2M$1.00
FY 2025$34.3M$-46.6M$-3.63
Q3 2025$13.0K$-21.8M$-1.84

Analyst Ratings

Consensus

Buy

Target (Consensus)

$19.50

Target (Median)

$19.50

Target Range

$19.00 - $20.00

Strong Buy: 0Buy: 5Hold: 0Sell: 0Strong Sell: 0
HC Wainwright & Co.Buy
2026-05-27

Trading Activity

Insider Trades

Buehler Kevindirector
Sell2026-06-05
Pire Shari Lisadirector
Sell2026-06-05
Germano Geno Jdirector
Sell2026-06-05
Frankel Stanleydirector
Sell2026-06-05
Brown Melindadirector
Sell2026-06-05

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

Beta

1.28

Precision BioSciences, Inc. is a clinical-stage biotechnology firm based in the United States, specializing in the creation of both in vivo gene editing solutions and ex vivo allogeneic CAR T-cell therapies. At its core is ARCUS, a proprietary genome editing platform designed to address and potentially cure genetic diseases. The company's portfolio also encompasses Ex vivo Allogeneic CAR T Immunotherapy, an innovative approach where specific immune cells, known as T-cells, are genetically modified outside the body to precisely identify and eliminate cancer cells. Among its prominent therapeutic candidates are: PBCAR0191, currently undergoing Phase 1/2a clinical trials for adult patients battling relapsed/refractory (R/R) non-Hodgkin lymphoma or R/R B-cell precursor acute lymphoblastic leukemia (B-ALL). PBCAR19B, an anti-CD19 CAR T candidate leveraging a "stealth cell" platform through a single-step gene edit, engineered to reduce the likelihood of chromosomal abnormalities. PBCAR269A, an investigational allogeneic CAR T immunotherapy formulated to target BCMA, intended for the treatment of R/R multiple myeloma. Precision BioSciences has strategically formed several collaborative alliances. These include an agreement with Les Laboratoires Servier for the development and commercialization of allogeneic chimeric antigen receptor T-cell therapies, aimed at various antigen targets, including hematological cancers beyond CD19, and solid tumors. The company is also partnering with Tiziana Life Sciences to assess foralumab, a fully human anti-CD3 monoclonal antibody, for its utility as a lymphodepleting agent in potential cancer treatments. Furthermore, a collaboration with iECURE, Inc. focuses on advancing ARCUS-based gene editing therapies. Established in 2006, Precision BioSciences, Inc. maintains its corporate headquarters in Durham, North Carolina.